SEC Form 4 · accession 0001123292-16-002944
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geraldine Henwood
Officer — President and CEO · Director
Period of report
Aug 1, 2016
Accepted (ET)
Nov 3, 2016 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.41 | Aug 1, 2016 | A | 52,650 | A | Aug 1, 2016 | Dec 16, 2025 | Common Stock | 52,650 | 52,650 | D |
Explanation of responses
- F1On December 16, 2015, the reporting person was granted an option to purchase 105,300 shares of common stock. The option vests in two equal installments upon satisfaction of certain performance conditions. On August 1, 2016, the Compensation Committee of the Board of Directors of the Issuer determined that the first performance condition was met, resulting in vesting of 50% of the option.